EURON WORKSHOP
Psychopharmacology: from laboratory to clinic

Oct. 7 - 11 2017
University of Crete

Organization
European Graduate School of Neuroscience (EURON)
- Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience (MHeN) and
- Faculty of Psychology and Neuroscience, Department Neuropsychology and Psychopharmacology
Maastricht University, Maastricht, The Netherlands

* Dr Arjan Blokland
* Dr Jos Prickaerts
* Prof. Wim Riedel
* Dr Nicole Senden
* Prof. Harry Steinbusch

in collaboration with the
University of Crete, Heraklion, Greece
* Prof. Domna Karagogeos
* Prof. Kyriaki Thermos
University of Crete, School of Medicine
SATURDAY OCT 7\textsuperscript{TH} - REGISTRATION AND OPENING LECTURE

\textbf{Location: University of Crete Medical School, Amphitheater 7A}

08.00 - 09.00  Registration

09.00 - 09.30  Arjan Blokland (Maastricht University, NL) & Kiki Thermos (University of Crete, Greece) – Opening, Introduction and General information

09.30 - 09.45  Harry Steinbusch (Maastricht University, NL) - European Graduate School of Neuroscience

09.45 - 10.15  Harry Steinbusch (Maastricht University, NL) - Failures and New Strategies in Drug Treatments for Alzheimer’s Disease

10.15 - 10.45  Break

10.45 - 11.45  Brian Leonard (National University of Galway, Ireland) - The future of depression research: the search for a new generation of antidepressants

\textbf{NEURODEGENERATION - ALZHEIMER'S DISEASE}

11.45 - 12.45  Jos Prickaerts (Maastricht University, NL) - Treating cognition in AD

12.45 - 13.30  Lunch

13.30 - 14.30  Daniela Puzzo (University of Catania, Italy) - The role of cGMP in modulating beta-amyloid production and function in the healthy and AD brain

14.30 - 16.00  Interactive sessions (Rooms: 7A-01, 7A-02, 7A-04)

\begin{itemize}
  \item Workshop 1  There are no neurological diseases (Harald Schmidt)
  \item Workshop 2  Pills are not the future, gene therapy might be (Jos Prickaerts)
  \item Workshop 3  Animal models of psychiatric disorders are of minimal relevance for the development of novel psychotropic drugs and have contributed to the lack of significant progress in the therapeutic advance in recent years (Brian Leonard)
\end{itemize}

16.00 - 16.30  Break

16.30 - 17.30  Plenary presentation and discussion workshops

18.30  Dinner “Petousis Restaurant”

SUNDAY OCT 8\textsuperscript{TH} - NEURODEVELOPMENT

\textbf{Amphitheater 7A}

09.00 - 10.00  Martien Kas (Groningen University, NL) - \textit{mTOR in developmental disorders}
10.00 - 11.00 Barbara Biemans (Roche, Basel) – *Vasopressin 1a receptor antagonism as a treatment for autism*

11.00 - 11.30 Break

11.30 - 12.15 Judith Homberg (Nijmegen University, NL) - *Early SSRI exposure and Neurodevelopmental Disorders*

12.15 - 13.00 Interactive sessions - Part I(Rooms: 7A -01, 7A -02, 7A -04)

  Workshop 1 *Which type of validity should we trust (more) for translational animal studies? Face, construct or predictive?* (Barbara Biemans)

  Workshop 2 *Neurodevelopment versus neurotransmission: what makes the difference?* (Judith Homberg)

  Workshop 3 *The fake validity of animal models in psychopharmacology* (Arjan Blokland)

13.00 - 14.00 Lunch

14.00 - 14.45 Interactive sessions - Part 2: Workshop 1-2-3

14.45 - 15.15 Break

15.15 - 16.45 Elevator pitch session PhD students – 1 (number 1-13)

16.45 - 17.30 Plenary presentations and discussion workshops

17.30 - 18.30 Poster presentations PhD students – 1 (number 1 – 13)

  Free night for students

20.30 Dinner for staff and organization – "Peskesi Restaurant"

**MONDAY OCT 9TH - NEUROPSYCHIATRY**

Amphitheater 7A

09.00 - 10.00 Arjan Blokland (Maastricht University, NL) - *Drugs versus Deep Brain Stimulation*

10.00 - 11.00 George Panagis (University of Crete, Greece) - *Drugs of abuse and reward systems*

11.00 - 12.30 Elevator pitch session PhD students – 2 (number 14 – 26)

12.30 - 13.30 Lunch

13.30 - 14.30 Panagiotis Bitsios (University of Crete, Greece) - *Animal models and risk factors for schizophrenia*

14.30 - 15.30 Poster presentations PhD students – 2 (number 14 -26)

16.00 - 20.00 City Tour and visit to the Archaeological Museum

20.30 Dinner "Merastri Restaurant"
TUESDAY OCT 10TH - DRUGS OF ABUSE: A THERAPEUTIC POTENTIAL?

Amphitheater 7A

09.00 - 10.00 Kim Kuypers (Maastricht University, NL) - Acute and long term effects of classical drugs of reward and abuse on cognition and social behavior (e.g. alcohol, MDMA, cannabis, cocaine)

10.00 - 11.00 Tomas Palenicek (NIMH, Czech Republic) - Acute and long-term effects of the 'new kids on the block' (novel psycho-active substances) on physiological and behavioral parameters/receptors profile

11.00 - 11.30 Break

11.30 - 12.30 Jordi Riba (University of Barcelona, Spain) - Acute and long-term effects of psychedelics and their therapeutic potential

12.30 - 13.30 Lunch

13.30 - 15.00 Interactive sessions – Part I (Rooms: 7A -01, 7A -02, 7A -04)

  Workshop 1 There is no such thing as an inverted U-shape dose response relationship (Wim Riedel)

  Workshop 2 Availability of MDMA-assisted psychotherapy should not be limited by the patient’s age (Kim Kuypers)

  Workshop 3 Ecstasy, acid or cathinones and NBOMe’s - are novel psychoactive substances (NPSs) valuable research tools or just drugs? (Tomas Palenicek)

15.00 - 15.30 Break

15.30 - 16.30 Plenary presentation and discussion workshops

19.00 Dinner with music - LIGA AP’OLA Restaurant

WEDNESDAY OCT 11TH - DRUG DEVELOPMENT

Amphitheater 7A

09.00 - 09.45 Harald Schmidt (Maastricht University, NL) - Drug Development in Stroke

09.45 - 10.30 Massimo Bani (UCB, Brussels, B) - CNS drug development: towards mechanistic predictions

10.30 - 11.00 Break

11.00 - 11.45 John Bothmer (Grünenthal GmbH, Aachen, G) - Drug development in Pain

11.45 - 12.30 Wim Riedel (Maastricht University) – Drug Development and Neurohealth

12.30 - 13.00 Discussion & Roundup
FACULTY LIST / ORGANIZERS

Dr. Massimo Bani, Global Head Clinical Pharmacology, UCB Pharma, Brussels, Belgium | Massimo.bani@ucb.com

Dr. Barbara Biemans, Laboratory Head Developmental & Behavioral Neuroscience, F. Hoffmann-La-Roche, Basel, Switzerland | barbara.biemans@roche.com

Prof. Panos Bitsios, Prof. of Psychiatry, Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Crete, Heraklion, Greece | pbitsios@med.uoc.gr

Dr. Arjan Blokland, Associated Prof. Section Psychopharmacology, Neuropsychology & Psychopharmacology Departments, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands | a.blokland@maastrichtuniversity.nl

Dr. John Bothmer, Innovation Unit Pain, Grünenthal GmbH, Aachen, Germany | john.bothmer@grunenthal.com

Dr. Judith Homberg, Department of Cognitive Neuroscience, Group Behavioural Neurogenetics, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre (RUMC), Nijmegen, The Netherlands | j.homberg@cns.umcn.nl

Prof. Dr. Domna Karagogeos, Prof. of Molecular Biology, Developmental Neurobiology, School of Medicine, University of Crete, Heraklion, Greece | karagoge@imbb.forth.gr

Prof. Dr. Martien Kas, Prof. of Behavioral Neuroscience, Faculty of Science and Engineering, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands | m.j.h.kas@rug.nl

Dr. Kim Kuypers, Ass. Prof. Section Psychopharmacology, Dept. Neuropsychology & Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands | k.kuypers@maastrichtuniversity.nl

Prof. Brian Leonard, Em. Prof. Pharmacology, National University of Galway, Ireland | brian@psycholeonard.com

Prof. George Panagis, Prof. of Biopsychology, Dept. of Psychology, University of Crete, Rethymno, Greece | panagis@uoc.gr

Dr. Tomas Palenicek, National Institute of Mental Health, Czech Republic | tomas.palenicek@nudz.cz

Dr. Jos Prickaerts, Associated Prof. Experimental Neuropsychopharmacology, Dept. Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands | jos.prickaerts@maastrichtuniversity.nl

Dr. Daniela Puzzo, Associate Prof. Neurophysiology, Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Italy | danypuzzo@yahoo.it

Dr. Jordi Riba, Sant-Pau Institute of Biomedical Research, Research Group Human Neuropsychopharmacology, University of Barcelona, Spain | jriba@santpau.cat
Prof. Wim Riedel, Prof. of Experimental Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands | w.riedel@maastrichtuniversity.nl

Prof. Harald Schmidt, Prof. of Pharmacology, Dept. of Pharmacology and Personalised Medicine, School for Cardiovascular Diseases, Fac. Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands | h.schmidt@maastrichtuniversity.nl

Dr. Nicole Senden, Programme Coordinator EURON, Maastricht University, Maastricht, The Netherlands | secr.euron@maastrichtuniversity.nl

Prof. Harry Steinbusch, Prof. in Cellular Neuroscience, Director EURON-European Graduate School for Neuroscience, Faculty Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands | h.steinbusch@maastrichtuniversity.nl

Prof. Kyriaki (Kiki) Thermos, Prof. of Pharmacology, School of Medicine, University of Crete, Heraklion, Crete, Greece | thermos@uoc.gr
LOCATIONS MEETING:

University of Crete Medical School

Amphitheater 7A* = lectures and elevator pitches
(* corridor 7A= Graduate Building)

Workshops 1,2,3 = Rooms: 7A -01, 7A -02, 7A -04

POSTER AND ORAL PRESENTATIONS PARTICIPANTS:

Abstracts: the abstracts will be presented on the intranet of the EURON website: www.euronschool.eu. The login code will be send by email.

Poster and elevator pitch presentations: the participants (who have submitted an abstract) will be asked to present their research work via a poster and via an elevator pitch.

Poster format frames are 0.95 width - 1.40 height.
Elevator pitch: the duration of the pitches is 5 min. Maximum of 5 slides per person: "name and group info, topic, hypothesis, results and conclusions”.

<table>
<thead>
<tr>
<th>Poster number / elevator pitch presentation</th>
<th>Session 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Role of PDE inhibitors on AMPA receptor trafficking and downstream cyclic nucleotide signaling</td>
</tr>
<tr>
<td>2</td>
<td>Post mortem evaluation of a new device for ocular drug delivery after cataract surgery</td>
</tr>
<tr>
<td>3</td>
<td>Effects of riociguat and biperiden on memory</td>
</tr>
<tr>
<td>4</td>
<td>SPRINT: can it enhance cognitive functioning in a young and healthy population?</td>
</tr>
<tr>
<td>5</td>
<td>Autophagy is required for the naturally occurring death of developing sensory neurons</td>
</tr>
<tr>
<td>6</td>
<td>Agmatine improves behavioral impairments observed in an animal model of the attention deficit hyperactivity disorder (ADHD)</td>
</tr>
<tr>
<td>7</td>
<td>Spike timing-dependent plasticity in adult and aged C57BL/6J mice</td>
</tr>
<tr>
<td>8</td>
<td>Electrophysiological effects of the PDE4 inhibitor roflumilast on the tri-phasic response of the substantia nigra pars reticulata</td>
</tr>
<tr>
<td>9</td>
<td>Effect of a novel TrkB agonist in mouse models of depression and Alzheimer’s disease</td>
</tr>
<tr>
<td>10</td>
<td>LOW PLASMATIC CONCENTRATIONS OF NR1 AND NR2 SUBUNITS OF N-METHYL-D-ASPARTATE RECEPTOR AS A POSSIBLE BIOMARKER FOR FIRST-EPIISODE OF PSYCHOSIS</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11</td>
<td>Brain Kinetics of Neurotransmission During THC Intoxication</td>
</tr>
<tr>
<td>12</td>
<td>Effect of acute and chronic ketamine on fluoxentine-induced antidepressant behavior</td>
</tr>
</tbody>
</table>

**Session 2**

| 13 | Understanding the effects of antagonists on α7 nicotinic acetylcholine receptors                                              | Dean Paes       |
| 14 | Modulation of 5-HT7 receptor: a new approach to the management of alcohol abuse and its neurobiological consequences?        | Eleni Paizanis  |
| 15 | HU-210 dose-dependently induces the downregulation of the CB1 cannabinoid receptor in rat retina                            | Sofia Papadogkonaki |
| 16 | The effect of HDAC inhibition on the extinction and reinstatement of the alcohol place-conditioned response                 | Tomas Paulauskas|
| 17 | GBA AND α-SYNUCLEIN: IS IT A TOXIC RELATIONSHIP?                                                                            | Alexia Polissidis|
| 18 | Reducing fear extinction deficits in mice with full 5-HT2C receptor editing, relevance for PTSD.                           | Mathilde Règue  |
| 19 | Cannabinoid type 2 receptor modulation and exercise actions on neurogenesis: impact for mood disorders                    | Rui Rodrigues   |
| 20 | Agmatine reverses emotional impairments in the intranasal MPTP model of Parkinson’s disease - The role of neurotrophic factors and neuroinflammation | Marissa G. Schamne |
| 21 | 3β-Methoxypregnenolone, a synthetic pregnenolone derivative, enhances neurite outgrowth and neuronal plasticity in neuronal culture | Marina Schverer |
| 22 | Rat 50-kHz ultrasonic vocalizations and glucocorticoid signaling: effects of corticosterone, mifepristone and metyrapone on calling initiation and on calling stimulated by social contacts or amphetamine. | Marcello Serra |
| 23 | Bumetanide and the treatment of behavioral problems in Tuberous Sclerosis Complex                                             | Dorinde M. van Andel |
| 24 | Antagonizing α7 nicotinic receptors with MLA potentiates synaptic plasticity and memory acquisition processes                | Nick P. van Goethem |
Biased post-synaptic 5-HT1A receptor stimulation as a potential treatment for schizophrenia related cognitive impairment in a ketamine rat model

Britt T. J. van Hagen

INFORMATION:

Email: secr.euron@maastrichtuniversity.nl

Website: http://www.euronschool.eu/nieuws/99/EURON_workshop:_Psychopharmacology:_from_laboratory_to_clinic/

At location: Sofia Papadogkonaki, PhD student, Help Desk, Medical School, University of Crete